Bladder Cancer Therapeutics and Diagnostics Market Size 2031
Bladder Cancer Therapeutics and Diagnostics Market Size 2031
Segments - Bladder Cancer Therapeutics and Diagnostics Market by Products (Therapeutics [Chemotherapy, Immunotherapy, and Others] and Diagnostics [Bladder Ultrasound, Cystoscopy, Urinalysis, and Others]), Cancer Types (Squamous Cell Bladder Cancer, Transitional Cell Bladder Cancer, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031
Upcoming
| Report ID :HC-3515
| 4.6 Rating
| 72 Reviews
| 200 Pages
| Format :
Report Description
Bladder Cancer Therapeutics and Diagnostics Market Outlook 2031:
The global bladder cancer therapeutics and diagnostics market size was valued at USD 266.10 Billion in 2022 and is projected to reach USD 430.84 Billion by 2031, expanding at a CAGR of 5.5% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising government initiatives to increase the awareness regarding bladder cancer.
Bladder cancer is the uncontrolled proliferation of abnormal cells in the epithelial cells of the urinary bladder lining. These cells evenly spread through the bladder's lining and into the muscular wall. Tumors are malignant tissues that can spread to other surrounding cells and tissues if they are not treated early. Bladder cancer is treated with urothelial carcinoma, squamous cell bladder cancer, and adenocarcinoma.
Several individuals and healthcare organizations have been affected by the coronavirus disease (COVID-19) pandemic caused by the acute respiratory distress syndrome coronavirus-2 (SARS-COV 2). The global economy was negatively impacted, which increased the burden on the healthcare infrastructure, hampering the market growth.
Bladder Cancer Therapeutics and Diagnostics Market Trend, Drivers, Restraints, and Opportunities
- Rising prevalence of tumors, medication developments, and technological advancements are accelerating the growth of bladder cancer therapies market.
- The presence of favorable reimbursement scenario is projected to boost the market expansion.
- Lack of treatment alternatives can hamper the global bladder cancer treatments market.
- High cost of treatment can hinder the market expansion.
- Increasing R&D activities and rising expenditure on healthcare infrastructure are expected to generate growth opportunities in the global bladder cancer therapies market.
Scope of the Bladder Cancer Therapeutics and Diagnostics Market Report
The report on the global bladder cancer therapeutics and diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Bladder Cancer Therapeutics and Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Products (Therapeutics [Chemotherapy, Immunotherapy, and Others] and Diagnostics [Bladder Ultrasound, Cystoscopy, Urinalysis, and Others]) and Cancer Types (Squamous Cell Bladder Cancer, Transitional Cell Bladder Cancer, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
GlaxoSmithKline PLC; Johnson & Johnson (Janssen Pharmaceutical); Bristol-Myers Squibb Company; AstraZeneca PLC; and F. Hoffmann-La Roche Ltd |
Bladder Cancer Therapeutics and Diagnostics Market Segment Insights
Cystoscopy segment is expected to grow at a rapid pace
Based on products, the market is divided into therapeutics, and diagnostics. The therapeutics segment is classified as chemotherapy, immunotherapy, and others. The diagnostics segment is further categorized as bladder ultrasound, cystoscopy, urinalysis, and others.
The cystoscopy segment is expected to grow at a rapid pace during the forecast period. Cystoscopy is a procedure that uses a telescope to look inside the bladder and urethra. Furthermore, cystoscope is a type of endoscope that is inserted into the bladder through the urethra and allows direct visual inspection of the urothelium.
Transitional cell bladder cancer segment is projected to expand at a considerable CAGR
On the basis of cancer types, the market is segregated into squamous cell bladder cancer, transitional cell bladder cancer, and others. The transitional cell bladder cancer segment is projected to expand at a considerable CAGR during the forecast period due to increasing prevalence of transitional cell bladder cancer. Moreover, rising number of diagnostic procedures is estimated to drive the segment growth.
North America is anticipated to constitute a key market share
In terms of regions, the global bladder cancer therapeutics and diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to constitute a key share of the market during the projected period due to expanding R&D activities and well-established healthcare infrastructure in the region.
Moreover, the existence of significant number of biologics and biopharmaceutical businesses is also contributing to the bladder cancer therapies and diagnostics market in North America.
Segments
The global bladder cancer therapeutics and diagnostics market has been segmented on the basis of
Products
- Therapeutics
- Chemotherapy
- Immunotherapy
- Others
- Diagnostics
- Bladder Ultrasound
- Cystoscopy
- Urinalysis
- Others
Cancer Types
- Squamous Cell Bladder Cancer
- Transitional Cell Bladder Cancer,
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- GlaxoSmithKline PLC
- Johnson & Johnson (Janssen Pharmaceutical)
- Bristol-Myers Squibb Company
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd
Competitive Landscape
Key players competing in the global bladder cancer therapeutics and diagnostics market are GlaxoSmithKline PLC; Johnson & Johnson (Janssen Pharmaceutical); Bristol-Myers Squibb Company; AstraZeneca PLC; and F. Hoffmann-La Roche Ltd.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Bladder Cancer Therapeutics and Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Bladder Cancer Therapeutics and Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Bladder Cancer Therapeutics and Diagnostics Market - Supply Chain
4.5. Global Bladder Cancer Therapeutics and Diagnostics Market Forecast
4.5.1. Bladder Cancer Therapeutics and Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Bladder Cancer Therapeutics and Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Bladder Cancer Therapeutics and Diagnostics Market Absolute $ Opportunity
5. Global Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Bladder Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Bladder Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
6. North America Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Bladder Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Bladder Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
7. Latin America Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Bladder Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Bladder Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
8. Europe Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Bladder Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Bladder Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
9. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
10. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Bladder Cancer Therapeutics and Diagnostics Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Bladder Cancer Therapeutics and Diagnostics Market: Market Share Analysis
11.2. Bladder Cancer Therapeutics and Diagnostics Distributors and Customers
11.3. Bladder Cancer Therapeutics and Diagnostics Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
Methodology
Related Reports
Some other reports from this category!
Our Clients
